Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential.
alternative splicing
hnRNPs
pan-cancer
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
01
02
2020
revised:
23
05
2020
accepted:
12
06
2020
pubmed:
12
9
2020
medline:
7
5
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
As the most critical alternative splicing regulator, heterogeneous nuclear ribonucleoproteins (hnRNPs) have been reported to be implicated in various aspects of cancer. However, the comprehensive understanding of hnRNPs in cancer is still lacking. The molecular alterations and clinical relevance of hnRNP genes were systematically analysed in 33 cancer types based on next-generation sequence data. The expression, mutation, copy number variation, functional pathways, immune cell correlations and prognostic value of hnRNPs were investigated across different cancer types. HNRNPA1 and HNRNPAB were highly expressed in most tumours. HNRNPM, HNRNPUL1, and HNRNPL showed high mutation frequencies, and most hnRNP genes were frequently mutated in uterine corpus endometrial carcinoma (UCEC). HNRNPA2B1 showed widespread copy number amplification across various cancer types. HNRNPs participated in cancer-related pathways including protein secretion, mitotic spindle, G2/M checkpoint, DNA repair, IL6/JAK/STAT3 signal and coagulation, of which hnRNP genes of HNRNPF, HNRNPH2, HNRNPU and HNRNPUL1 are more likely to be implicated. Significant correlation of hnRNP genes with T help cells, NK cells, CD8 positive T cells and neutrophils was identified. Most hnRNPs were associated with worse survival of adrenocortical carcinoma (ACC), liver hepatocellular carcinoma (LIHC) and lung adenocarcinoma (LUAD), whereas hnRNPs predicted better prognosis in kidney renal clear cell carcinoma (KIRC) and thymoma (THYM). The prognosis analysis of KIRC suggested that hnRNPs gene cluster was significantly associated with overall survival (HR = 0.5, 95% CI = 0.35-0.73, P = 0.003). These findings provide novel evidence for further investigation of hnRNPs in the development and therapy of cancer in the future.
Identifiants
pubmed: 32915499
doi: 10.1111/jcmm.15558
pmc: PMC7576281
doi:
Substances chimiques
Heterogeneous-Nuclear Ribonucleoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11111-11119Informations de copyright
© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Int J Mol Sci. 2019 Feb 10;20(3):
pubmed: 30744200
Am J Hum Genet. 2018 Jan 4;102(1):11-26
pubmed: 29304370
Hum Genet. 2016 Aug;135(8):851-67
pubmed: 27215579
J Transl Med. 2015 Aug 30;13:285
pubmed: 26318153
Hum Pathol. 2011 Mar;42(3):393-402
pubmed: 21194727
Genes Dev. 2014 Jun 1;28(11):1191-203
pubmed: 24840202
Genes Chromosomes Cancer. 2017 Aug;56(8):598-607
pubmed: 28393427
Oncol Rep. 2018 Apr;39(4):1693-1701
pubmed: 29484423
J Cancer Res Ther. 2013 Nov;9 Suppl:S129-34
pubmed: 24516048
J Cell Physiol. 2015 Sep;230(9):2252-61
pubmed: 25752295
Biomed Res Int. 2013;2013:623978
pubmed: 23984388
Wiley Interdiscip Rev RNA. 2018 May;9(3):e1468
pubmed: 29423937
Future Oncol. 2015;11(23):3207-18
pubmed: 26551559
J Cell Mol Med. 2020 Oct;24(19):11111-11119
pubmed: 32915499
J Immunol. 2017 Nov 15;199(10):3571-3582
pubmed: 28993514
Annu Rev Cell Dev Biol. 2018 Oct 6;34:451-469
pubmed: 30028642
Nucleic Acids Res. 2017 Jul 27;45(13):7950-7964
pubmed: 28520992
Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5207-E5215
pubmed: 28611215
Biochem J. 2017 Mar 7;474(6):885-896
pubmed: 28270561
Int J Oncol. 2017 Jul;51(1):169-183
pubmed: 28560430
World J Gastroenterol. 2014 Dec 14;20(46):17305-13
pubmed: 25516641
Cancer Res. 2014 May 15;74(10):2750-62
pubmed: 24638979
RNA. 2010 Aug;16(8):1449-62
pubmed: 20584894
Prostate. 2019 Aug;79(11):1199-1210
pubmed: 31251827
EBioMedicine. 2019 Mar;41:299-309
pubmed: 30852162
Oncogene. 2010 Apr 29;29(17):2457-66
pubmed: 20190808
Gene. 2016 Feb 1;576(2 Pt 2):791-7
pubmed: 26581508
Wiley Interdiscip Rev RNA. 2018 Jul;9(4):e1476
pubmed: 29693319
Acta Pharmacol Sin. 2015 Oct;36(10):1212-8
pubmed: 26073330
Adv Exp Med Biol. 2007;623:123-47
pubmed: 18380344
Oncogene. 2018 May;37(20):2728-2745
pubmed: 29511351
Trends Genet. 2002 Apr;18(4):186-93
pubmed: 11932019
Saudi Med J. 2019 Apr;40(4):328-338
pubmed: 30957125